Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ultragenyx Pharmaceutical Inc. (RARE : NSDQ)

• Company Description    Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Number of Employees: 1,119

• Price / Volume Information    Yesterday's Closing Price: $51.47 Daily Weekly Monthly 20 Day Moving Average: 538,157 shares Shares Outstanding: 69.93 (millions) Market Capitalization: $3,599.31 (millions) Beta: 1.58 52 Week High: $115.25 52 Week Low: $49.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -39.73% -34.21% 12 Week -22.84% -16.61% Year To Date -38.79% -27.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 Leveroni Court - Novato,CA 94949 USA ph: 415-483-8800 fax: 415-483-8810 ir@ultragenyx.com http://www.ultragenyx.com

• General Corporate Information    Officers Emil D. Kakkis - President and Chief Executive Officer and Director Daniel G. Welch - Chairman Mardi C. Dier - Executive Vice President and Chief Financial Offic Theodore A. Huizenga - Senior Vice President; Corporate Controller William Aliski - Director Peer Information Ultragenyx Pharmaceutical Inc. (CORR.) Ultragenyx Pharmaceutical Inc. (RSPI) Ultragenyx Pharmaceutical Inc. (CGXP) Ultragenyx Pharmaceutical Inc. (BGEN) Ultragenyx Pharmaceutical Inc. (GTBP) Ultragenyx Pharmaceutical Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90400D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/01/22 Share - Related Items Shares Outstanding: 69.93 Most Recent Split Date: (:1) Beta: 1.58 Market Capitalization: $3,599.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/01/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.48 Price/Cash Flow: - Price / Sales: 10.84 EPS Growth vs. Year Ago Period: -7.88% vs. Previous Quarter: -22.35% Sales Growth vs. Year Ago Period: -19.58% vs. Previous Quarter: -4.14% ROE 03/31/22 - -49.18 12/31/21 - -44.24 09/30/21 - -38.25 ROA 03/31/22 - -30.20 12/31/21 - -28.08 09/30/21 - -24.77 Current Ratio 03/31/22 - 4.23 12/31/21 - 4.72 09/30/21 - 6.23 Quick Ratio 03/31/22 - 4.12 12/31/21 - 4.63 09/30/21 - 6.12 Operating Margin 03/31/22 - -134.26 12/31/21 - -122.22 09/30/21 - -109.44 Net Margin 03/31/22 - -141.65 12/31/21 - -129.20 09/30/21 - -98.89 Pre-Tax Margin 03/31/22 - -141.28 12/31/21 - -128.90 09/30/21 - -98.59 Book Value 03/31/22 - 11.48 12/31/21 - 13.53 09/30/21 - 13.70 Inventory Turnover 03/31/22 - 1.05 12/31/21 - 1.09 09/30/21 - 1.29 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©